GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
Mechelen, Belgium; 20 May 2018; 20.30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces publication milestones on GLPG1690 in idiopathic pulmonary fibrosis (IPF). In addition to presenting three abstracts on investigational drug GLPG1690 at the American Thoracic Society Meeting (ATS) from 18 to 23 May in San Diego, California, USA, Galapagos announces the publication of the FLORA Phase 2a study results in the most recent issue of The Lancet Respiratory Medicine.
"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis: a phase 2a randomised placebo-controlled trial (FLORA trial)," by Prof. Dr. Toby Maher et al. describes the FLORA trial results and was published today in The Lancet Respiratory Medicine.
FLORA was an exploratory, randomized, double-blind, placebo-controlled trial investigating a once-daily oral dose of GLPG1690. The drug candidate was administered for 12 weeks in 23 IPF patients, 17 of whom received GLPG1690 and 6 of whom received placebo. Over the 12-week period, patients receiving GLPG1690 showed an FVC increase of 8 mL, while patients on placebo showed an FVC reduction of 87 mL (mean from baseline). GLPG1690 was well-tolerated by IPF patients in the FLORA trial.
"Although not without limitations, proof of concept studies are vital in addressing the huge unmet need for effective and well tolerated therapies for idiopathic pulmonary fibrosis, a progressive and inevitably fatal lung disease. Studies such as FLORA quickly support proof-of-concept of new treatment options, without unnecessarily exposing high-risk patients to investigational therapies of unknown efficacy for prolonged periods of time," said Dr. Toby Maher, British Lung Foundation Chair in Respiratory Research and Professor of Interstitial Lung Disease, Imperial College, London, in The Lancet Respiratory Medicine publication. "Although measuring effect of treatment was only a secondary, non-powered endpoint, the data from FLORA, particularly for FVC, are extremely encouraging and warrant further larger scale trials." A link to this publication can be found at www.glpg.com/glpg-1690.
At ATS in San Diego, the Galapagos team are in de midst of presenting the following abstracts:
Sunday May 20, 2018 9:15 AM - 4:15 PM - poster session
9869 - Pharmacodynamics and Pharmacokinetics of the Autotaxin Inhibitor GLPG1690 in the FLORA Trial: a Randomized, Placebo-controlled, Double Blind Phase IIa Clinical Trial of 12 Weeks in Individuals with Idiopathic Pulmonary Fibrosis
Sunday May 20, 2018 2:15 PM-4:15 PM - oral presentation
9097 - Randomized, Placebo-Controlled, Double Blind Phase IIa Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment of an Autotaxin Inhibitor (GLPG1690) in Individuals with Idiopathic Pulmonary Fibrosis (FLORA Trial)
Tuesday May 22, 2018 2:15 PM - 4:15 PM - oral presentation
8893 - Assessment of the Effects of GLPG1690 in Idiopathic Pulmonary Disease (IPF) Patients Using Functional Respiratory Imaging (FRI)
GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule GLPG1690 as an inhibitor of this target. Oral investigational drug GLPG1690 showed promising results in relevant pre-clinical models for IPF, and there is growing evidence in scientific literature that autotaxin plays a role in this disease. GLPG1690 appeared to halt disease progression as measured by FVC at 12 weeks and was well-tolerated by IPF patients in the FLORA Phase 2a trial reported in August 2017. Galapagos received orphan drug designation for GLPG1690 in IPF from the U.S. Food & Drug Administration (FDA) and European Commission (EC). In April 2018, Galapagos announced the design of a worldwide Phase 3 program, based on feedback from the FDA and the European Medicines Agency (EMA), to evaluate GLPG1690 in IPF patients. The planned ISABELA Phase 3 program with GLPG1690 is intended to support both New Drug Application (NDA) and Market Authorization Application (MAA) submissions in respectively the United States and European Union. GLPG1690 is an investigational drug and its efficacy and safety have not been established.